B-Cell Lymphoma/leukemia 10 (BCL10) Antibody

Este producto es parte de BCL10 immune signaling adaptor
B-Cell Lymphoma/leukemia 10 (BCL10) Antibody

Pida mas información

935106861

info@markelab.com

Precio

338€ (60 µl)

Antibody anti-BCL10

proveedor

Abbexa

reference

abx001024

Tested Applications

WB

reactivity

Human

status

RUO

clonality

Polyclonal

Descripción

BCL10 Antibody is a Rabbit Polyclonal antibody against BCL10. This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.


Background

B-cell lymphoma/leukemia 10 (BCL10) is an essential signaling molecule involved in the regulation of immune cell activation, particularly in T-cell and B-cell responses BCL10 functions as a scaffolding protein in the activation of the NF-κB pathway, which is crucial for regulating inflammation, immune responses, and cell survival BCL10 forms a complex with other proteins, such as MALT1, to initiate signaling cascades that lead to immune cell activation and proliferation Its dysregulation has been linked to lymphoid malignancies, such as MALT lymphoma, where mutations or overexpression of BCL10 promote cancer cell proliferation and survival BCL10 is also involved in the regulation of apoptosis and cell differentiation, particularly in the context of immune cell maturation In addition to its role in immune cells, BCL10 has been shown to influence inflammatory diseases and autoimmunity, making it a potential target for therapeutic intervention

Características del producto

category

Primary Antibodies


clonality

Polyclonal


reactivity

Human


immunogen target

B-Cell Lymphoma/leukemia 10 (BCL10)


host

Rabbit


isotype

IgG


conjugation

Unconjugated


form

Liquid


tested applications

WB


purification

Purified by affinity chromatography.


recommended dilution

WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user.


buffer

PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol.


size 1

60 µl


size 2

120 µl


size 3

200 µl


storage

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.


or code

BCL10


dry ice

No


availability

Shipped within 5-10 working days.


alias

CARMEN,CIPER,CLAP,IMD37,c-E10 Me10,CARD-containing molecule enhancing NF-kappa-B,CARD-like apoptotic protein, hCLAP


NCBI accession

NP_003912.1


note

Concentration: 1 mg/ml -


Quizá le pueda interesar

Rat Bcl10(B-cell lymphoma/leukemia 10) ELISA Kit

Rat Bcl10(B-cell lymphoma/leukemia 10) ELISA Kit

proveedor

FineTest

reference

ER0707

reactivity

rat

status

RUO

Precio a consultar

Ver más

anti- BCL10 antibody

anti- BCL10 antibody

proveedor

FineTest

reference

FNab00835

Tested Applications

ELISA, WB, IHC

reactivity

human,mouse,rat

status

RUO

clonality

polyclonal

Involved in adaptive immune response(PubMed:25365219). Promotes apoptosis, pro-caspase-9 maturation and activation of NF...

Precio a consultar

Ver más

anti- BCL10 antibody

anti- BCL10 antibody

proveedor

FineTest

reference

FNab00836

Tested Applications

ELISA, WB, IHC

reactivity

human,mouse

status

RUO

clonality

polyclonal

Involved in adaptive immune response(PubMed:25365219). Promotes apoptosis, pro-caspase-9 maturation and activation of NF...

Precio a consultar

Ver más